[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Todd C. Lee MD MPH FIDSA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,81,107,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100565065","phase-4-daptomycin-vs-vancomycin-for-the-treatment-of-methicillin-resistant-s-aureus-bacteremia-100565065",false,"NCT06637332","Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia","DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia","DAPTO-SNAP","The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:\n\nInclusion Criteria:\n\n* Methicillin-resistant S. aureus bacteremia\n\nExclusion Criteria:\n\n* Severe allergy or non-severe rash to vancomycin or daptomycin\n* Suspected or confirmed MRSA pneumonia\n* Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg\u002FL or daptomycin MIC greater than or equal to 1mg\u002FL","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.\n\nThis study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)",[27,28,29,30,31],"Staphylococcus Aureus Septicemia","Staphylococcus Aureus Bacteremia","S. Aureus Bacteremia","S. Aureus Bloodstream Infection","Staphylococcus Aureus Endocarditis",[33,34,35,36,37,38],"S. aureus bacteremia","Methicllin resistant","MRSA","S. aureus bloodstream infection","Daptomycin","Vancomycin","RECRUITING","2026-06-18",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":43},"2024-11-14",{"date":47,"type":21},"2027-11",{"name":49,"class":50},"Todd C. Lee MD MPH FIDSA","OTHER",17,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100430531","phase-2-combination-cefazolin-with-ertapenem-for-methicillin-susceptible-staphylococcus-aureus-bacteremia-100430531","NCT04886284","Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia","Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)","CERT","The participant must fulfil all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria to be eligible for this sub-study:\n\nInclusion Criteria:\n\n1. Adult \\>=18 years old\n2. S. aureus bacteremia within the past 48 hours:\n\n   * with any unknown MRSA status (in centers with \\\u003C15% prevalence of MRSA in their annual blood cultures) or known negative MRSA screening swab within 90 days OR\n   * which has already been shown to be MSSA\n3. Current receipt of cefazolin or where it would be clinically appropriate (according to treating ID specialist) to switch to cefazolin as the backbone therapy (open label, non-study drug).\n\nNOTE: Up to an additional 12-24 hours of open label non-study VANCOMYCIN, LINEZOLID or DAPTOMYCIN may be allowed if there is sepsis and clinical concern for MRSA has not been excluded.\n\nExclusion Criteria:\n\nClinical:\n\n1. At time of recruitment, the patient has already clinically improved with at least one subsequent negative culture at \\>24 hours incubation\n2. Anaphylaxis to any beta-lactam antibiotic (and any allergy to ertapenem) Polymicrobial bacteremia (not including skin commensals)\n3. Known seizure disorder\n4. Any receipt of valproic acid\n5. Expected mortality within 48 hours\n6. Need for critical care resources but \"do not resuscitate\" status precludes the receipt of critical care\n7. Unable to provide informed consent and no available healthcare proxy (with ethics approval for deferred consent in cases of severe illness)\n\nAdministrative:\n\n1. Refusal to provide informed consent\n2. Refusal of healthcare team to participate\n3. No reliable means of outpatient contact (telephone\u002Femail\u002Ftext)\n4. Previously enrolled\n5. Patients whose isolate is identified as MRSA post-enrollment will be subsequently excluded (see below).\n\nNote that because MSSA is much more common than MRSA in Canada (90% of all S. aureus bacteremia at MUHC, for example, are MSSA and in the presence of a negative MRSA screening swab or unknown MRSA status, this means that the risk of MRSA is less than 5%). We believe time to combination therapy is likely linked to benefit, therefore we will recruit the patients as soon as S. aureus is identified but potentially prior to confirmation the organism is MSSA. Where possible, rapid MRSA detection techniques will be deployed; however with conventional screening this will mean approximately a 12-24 hours delay. Organisms subsequently identified as MRSA will be excluded from the intention to treat analysis and the sample size will be adjusted accordingly to ensure the total enrollment meets study goals.","100 Years",{"count":62,"type":21},60,[64],"PHASE2","There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed.\n\nThis study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)",[28,27,67,31],"Staphylococcal Sepsis",[69,70,71],"Staphylococcus aureus","Methicillin-susceptible","Bacteremia","2026-05-22",{"date":74,"type":43},"2026-05-27",{"date":76,"type":43},"2024-05-20",{"date":78,"type":21},"2027-07",{"name":49,"class":50},6,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100566077","phase-4-clopidogrel-vs-aspirin-for-cardiovascular-risk-reduction-in-patients-with-s-aureus-bacteremia-100566077","NCT06650488","Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia","Clopido-SNAP 2","The participant must meet all inclusion and exclusion criteria for the SNAP\n\nPlatform (NCT05137119) and also the following inclusion and exclusion criteria:\n\nInclusion Criteria:\n\n* Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral vascular disease)\n\nExclusion Criteria:\n\n* Active bleeding (allowing up to 3 days from platform entry to randomize in the event anti-thrombotic therapy is resumed)\n* Anticipated major cardiac surgery, neurosurgery, or spine surgery within the next 3 days\n* Pregnancy\n* Known receipt of clopidogrel, prasugrel, or ticagrelor within the last month\n* Allergy to clopidogrel\n* Concomitant receipt of oral Xa inhibitor",{"count":20,"type":21},[24],"This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.\n\nUnlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.\n\nThis study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).\n\nIf positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.",[31,27,92],"Staphylococcus Aureus Bloodstream Infection",[94,36,95,96,97],"S. aureus bactremia","S. aureus endocarditis","aspirin","clopidogrel","2026-03-17",{"date":100,"type":43},"2026-03-20",{"date":102,"type":43},"2026-01-15",{"date":104,"type":21},"2030-01",{"name":49,"class":50},1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":128,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":106},"100427823","phase-3-low-dose-trimethoprim-sulfamethoxazole-for-the-treatment-of-pneumocystis-jirovecii-pneumonia-100427823","NCT04851015","Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia","LOW-DOSE","Inclusion Criteria:\n\n* 18 years or older\n* Immunocompromised (including but not limited to HIV, solid organ transplant, solid tumors, hematological stem cell transplant and malignancies, systemic diseases, chemotherapy, long term corticosteroid use, and immunosuppressive therapies, as well as primary immunodeficiencies\n* Presentation to a day hospital, emergency department, or admitted to hospital\n* Proven or probable diagnosis of PCP using an adapted version of the 2021 EORTC\u002FMSGERC criteria.\n\nExclusion Criteria:\n\n* Previous severe adverse reaction to TMP-SMX, any sulfa drug, or any component of formulation\n* Compliant with PCP prophylaxis for ≥4 weeks with TMP-SMX at enrollment\n* More than 96 hours of any therapy for PCP\n* Hepatic impairment marked by alanine aminotransferase levels ≥5 times the upper limit of normal\n* Known G6PD deficiency\n* Known diagnosis of porphyria\n* Known pregnancy or breastfeeding (as per Health Canada)\n* Unable to provide informed consent and no available healthcare proxy (with ethics approval for deferred consent in cases of critical illness); refusal of consent; no reliable means of outpatient contact (telephone\u002Femail\u002Ftext);\n* Previously enrolled",{"count":115,"type":21},416,[117],"PHASE3","Pneumocystis jirovecii pneumonia (PCP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg\u002Fkg\u002Fday of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX.\n\nReduced treatment doses of TMP-SMX for PCP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg\u002Fkg\u002Fday of TMP) compared to the standard-of-care (15 mg\u002Fkg\u002Fday) among patients with PCP for the primary outcome of Win Ratio hierarchical composite of death, ECMO, invasive ventilation, grade 4 toxicity, non-invasive ventilation, change of therapy and length of stay.",[120,121,122,123,124,125,126,127],"Pneumocystis","Pneumocystis Pneumonia","Pneumocystis Jirovecii Infection","Pneumocystis Infections","Pneumocystis Carinii Infection","Pneumocystosis; Pneumonia (Etiology)","Pneumocystis Carinii; Infection, Resulting From HIV Disease","Pneumocystosis Associated With AIDS",[120,129,130,131,132,133],"PCP","PJP","immunosuppressed","HIV","TMP-SMX","2026-02-18",{"date":136,"type":43},"2026-02-20",{"date":138,"type":43},"2025-11-28",{"date":140,"type":21},"2030-12-31",{"name":49,"class":50},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":106},"100612446","phase-3-adjunctive-rifampin-for-the-treatment-of-prosthetic-valve-endocarditis-due-to-s-aureus-100612446","NCT07253688","Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus","Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus (RIFA-SNAP)","RIFA-SNAP","Inclusion Criteria:\n\n1. Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and\u002For aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable);\n2. Patient or healthcare proxy provide informed consent.\n\nExclusion Criteria:\n\n1. Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis \\\u003C 90 days according to the treating team;\n2. Patient requires intensive care but has a do not resuscitate order precluding transfer;\n3. Polymicrobial bacteremia (not including skin commensals or other recognized contaminant);\n4. Organism tests as rifampin resistant;\n5. History of hypersensitivity\u002Fanaphylaxis or severe adverse reaction to rifampin;\n6. Category X or other important drug-drug interaction with rifampin which cannot be safely mitigated \\[with as-needed consultation from experts from pharmacy and\u002For internal medicine\u002Fgeriatrics for potential deprescribing\\];\n7. Child Pugh Class C cirrhosis;\n8. Clinician deems rifampin to be mandatory;\n9. Patient has already received \\>3 days of rifampin at time of screening or \\>10 days of total therapy\n10. Pregnancy or breast feeding\n\nAdministrative exclusions:\n\n1. No reliable means of outpatient contact (telephone\u002Femail\u002Ftext);\n2. Previously enrolled;\n3. Prior S. aureus bacteremia within the preceding 180 days",{"count":151,"type":21},330,[117],"This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.",[31,155],"Prosthetic Valve Endocarditis",[33,157,158],"Prosthetic valve endocarditis","Rifampin","2025-12-04",{"date":161,"type":43},"2025-12-10",{"date":163,"type":43},"2025-11-10",{"date":165,"type":21},"2030-07",{"name":49,"class":50},""]